DK1276501T5 - Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi - Google Patents

Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Info

Publication number
DK1276501T5
DK1276501T5 DK01928938T DK01928938T DK1276501T5 DK 1276501 T5 DK1276501 T5 DK 1276501T5 DK 01928938 T DK01928938 T DK 01928938T DK 01928938 T DK01928938 T DK 01928938T DK 1276501 T5 DK1276501 T5 DK 1276501T5
Authority
DK
Denmark
Prior art keywords
photodynamic therapy
treating tumors
tumor
bearing
treating
Prior art date
Application number
DK01928938T
Other languages
Danish (da)
English (en)
Other versions
DK1276501T3 (da
Inventor
William C Fanslow Iii
Elaine K Thomas
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of DK1276501T3 publication Critical patent/DK1276501T3/da
Publication of DK1276501T5 publication Critical patent/DK1276501T5/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01928938T 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi DK1276501T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19954500P 2000-04-25 2000-04-25
PCT/US2001/013616 WO2001080888A2 (fr) 2000-04-25 2001-04-25 Procede de traitement des tumeurs par therapie photodynamique

Publications (2)

Publication Number Publication Date
DK1276501T3 DK1276501T3 (da) 2006-04-24
DK1276501T5 true DK1276501T5 (da) 2007-02-26

Family

ID=22737985

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01928938T DK1276501T5 (da) 2000-04-25 2001-04-25 Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi

Country Status (10)

Country Link
US (2) US20020041864A1 (fr)
EP (1) EP1276501B9 (fr)
AT (1) ATE313334T1 (fr)
AU (2) AU5574001A (fr)
CA (1) CA2407336A1 (fr)
DE (1) DE60116075T4 (fr)
DK (1) DK1276501T5 (fr)
ES (1) ES2254408T4 (fr)
PT (1) PT1276501E (fr)
WO (1) WO2001080888A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002234809B2 (en) * 2001-01-30 2005-04-07 Oncoquest Inc. Perylenequinones for use with immunotherapy agents
EP2359849A1 (fr) * 2001-04-02 2011-08-24 Genentech, Inc. Polytherapie
AU2003226082A1 (en) * 2002-03-25 2003-11-11 The General Hospital Corporation Methods of adjuvant photodynamic therapy to enhance radiation sensitization
US8372409B2 (en) * 2003-04-09 2013-02-12 University Of Florida Research Foundation, Inc. Dendritic cell binding proteins and uses thereof
CA2615510A1 (fr) 2005-08-10 2007-02-15 Quest Pharmatech Inc. Derives de perylenequinone et leurs utilisations
US8454991B2 (en) * 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
US20100255080A1 (en) * 2009-04-02 2010-10-07 Sesvalia Usa, Llc Liposomal ALA pharmaceutical and cosmeceutical compositions and methods of treatment
EP2718457A4 (fr) 2011-06-06 2014-12-24 Immungene Inc Molécules de fusion génétiquement modifiées ligand élément tnfsf-anticorps
EP3973973A1 (fr) 2017-10-31 2022-03-30 KaliVir Immunotherapeutics, Inc. Vecteur de plateforme oncolytique pour administration systémique
MX2021002289A (es) * 2018-08-29 2021-05-27 Shattuck Labs Inc Proteinas quimericas basadas en flt3l.
JP2022536935A (ja) * 2019-06-17 2022-08-22 エノキアン バイオファーマ インコーポレイテッド 細胞性免疫及び体液性免疫を誘導するための同種異系ｔ細胞ベースのｈｉｖワクチン
BR112023022681A2 (pt) 2021-04-30 2024-01-23 Kalivir Immunotherapeutics Inc Vírus oncolíticos para expressão modificada de mhc
AU2022292632A1 (en) * 2021-06-17 2023-12-21 Kalivir Immunotherapeutics, Inc. Tnfsf-l fusion proteins and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
CA2131003A1 (fr) * 1992-05-26 1993-12-09 Raymond G. Goodwin Nouvelle cytokine liant le cd30
JPH09507074A (ja) * 1993-12-23 1997-07-15 イミュネックス・コーポレーション Ｃｄ４０を発現する腫瘍細胞を特徴とする疾患の予防又は治療方法
US6495129B1 (en) * 1994-03-08 2002-12-17 Human Genome Sciences, Inc. Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3)
EA199800272A1 (ru) * 1995-10-04 1998-10-29 Иммунекс Корпорейшн Фактор, стимулирующий дендритные клетки
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6146409A (en) * 1996-05-20 2000-11-14 Bergein F. Overholt Therapeutic methods and devices for irradiating columnar environments
AU705647B2 (en) * 1996-07-10 1999-05-27 Immunex Corporation Method of activating dendritic cells
US6291661B1 (en) * 1998-07-02 2001-09-18 Immunex Corporation flt3-L mutants and method of use
WO2000051638A1 (fr) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Therapie photodynamique associee a des facteurs induisant l'apoptose
US6756141B2 (en) * 2001-04-17 2004-06-29 Southwest Research Institute Three-electrode fuel cell

Also Published As

Publication number Publication date
EP1276501A2 (fr) 2003-01-22
ES2254408T4 (es) 2007-10-01
EP1276501B9 (fr) 2007-01-24
WO2001080888A2 (fr) 2001-11-01
ES2254408T3 (es) 2006-06-16
AU5574001A (en) 2001-11-07
DE60116075D1 (de) 2006-01-26
DK1276501T3 (da) 2006-04-24
PT1276501E (pt) 2006-05-31
EP1276501B1 (fr) 2005-12-21
DE60116075T4 (de) 2007-06-06
DE60116075T2 (de) 2006-08-31
ATE313334T1 (de) 2006-01-15
WO2001080888A3 (fr) 2002-08-29
US20050129689A1 (en) 2005-06-16
US20020041864A1 (en) 2002-04-11
AU2001255740B2 (en) 2006-03-16
CA2407336A1 (fr) 2001-11-01

Similar Documents

Publication Publication Date Title
DK1276501T3 (da) Fremgangsmåde til behandling af tumorer under anvendelse af fotodynamisk terapi
NO20022065D0 (no) Terapeutisk anvendelse
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
BR0308928A (pt) Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular
WO2001082961A3 (fr) Procedes de traitement des tumeurs osseuses
DK1827500T3 (da) Pegyleret liposomal doxorubicin i kombination med ecteinescidin 743
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
WO2002066044A3 (fr) Procede de traitement de tumeurs utilisant une polytherapie
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
HK1101348A1 (en) Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation
ATE442861T1 (de) Gegen antikörper gerichtete photodynamische therapie
DK1689404T3 (da) Kombination af et-743 med 5-fluoracil-prodrugs til behandling af cancer
WO2000057911A3 (fr) Cellules mammaliennes conjuguees a un haptene, et methodes de preparation et d'utilisation correspondantes
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2001007028A3 (fr) Utilisation d'antagonistes de recepteurs de retinoides dans le traitement du cancer de la prostate
PT1051187E (pt) Tratamento de linfomas foliculares usando inibidores da via da linfotoxina (lt)
DK1185279T3 (da) Midler til behandling af maligne sygdomme ved anvendelse af proteinet YB-1
TW200724158A (en) Combination therapy in the treatment of cancer
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
WO2005041860A3 (fr) Cellules souches utilisees pour localiser et cibler des cellules tumorales
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
UA88294C2 (ru) ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК
WO2005006947A3 (fr) Cellules utilisees pour localiser et cibler des cellules tumorales